Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastrointest Oncol. Oct 15, 2011; 3(10): 137-143
Published online Oct 15, 2011. doi: 10.4251/wjgo.v3.i10.137
Table 4 Pathologic outcomes
Ref.PatientsSurgerySampleLN dissection (D1+αorβ/D2)LN harvested (number)Stage (Ia/Ib/II)
Anderson et al[27]1Gastric adenocarcinoma onlyRobot7-24 (17-30)2/2/2
Hyung et al[28]Gastric adenocarcinoma onlyInitial Robot10-34 (16-50)-
Initial Lap.10-29.2 (12-54)-
Recent Lap.10-37.8 (26-51)-
Patriti et al[29]Gastric adenocarcinoma onlyRobot13-28.1 ± 8.33/3/6
Pugliese et al[30]Gastric adenocarcinoma onlyRobot9-27.5 ± 5 (18-40)-
Lap.46-31.5 ± 9.5 (20-45)-
Song et al[31]Gastric adenocarcinoma onlyInitial Robot2016/435.3 ± 10.519/1/10
Initial Lap.2010/1031.5 ± 17.114/4/2
Recent Lap.2012/842.7 ± 14.919/0/1
Song et al[32]Gastric adenocarcinoma onlyRobot10058/4236.7 ± 13.3 (11-83)74/16/4
Hur et al[33]Gastric adenocarcinoma onlyRobot7---
Pugliese et al[34]Gastric adenocarcinoma onlyRobot16-25 ± 4.5 (18-40)-
Lap.48-31 ± 8 (20-45)-
Kim et al[35]Gastric adenocarcinoma onlyRobot162/1441.1 ± 10.9-
Lap.113/837.4 ± 10.0-
Open120/1243.3 ± 10.4-